{
    "2018-12-01": [
        [
            {
                "time": "2018-12-03",
                "original_text": "AbbVie Presents New Data from Phase 3 MURANO Trial of VENCLEXTA®/VENCLYXTO® (venetoclax) in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed the Fixed Treatment Course",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Phase 3",
                        "MURANO Trial",
                        "VENCLEXTA",
                        "VENCLYXTO",
                        "venetoclax",
                        "Rituximab",
                        "Relapsed/Refractory Chronic Lymphocytic Leukemia"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-12-03",
                "original_text": "3 Beaten-Down Biotech Stocks to Buy Before the End of 2018",
                "features": {
                    "keywords": [
                        "Beaten-Down",
                        "Biotech Stocks",
                        "Buy",
                        "End of 2018"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-12-03",
                "original_text": "Delayed Humira Biosimilar Boosts AbbVie's Fair Value",
                "features": {
                    "keywords": [
                        "Delayed",
                        "Humira",
                        "Biosimilar",
                        "Boosts",
                        "AbbVie",
                        "Fair Value"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}